Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s
Early Intervention Benefits?
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
You may also be interested in...
Growing use in liver cancer drives global sales of Lenvima along with the overall performance of Eisai.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.